𝔖 Bobbio Scriptorium
✦   LIBER   ✦

High-frequency rTMS over the supplementary motor area for treatment of Parkinson's disease

✍ Scribed by Masashi Hamada; Yoshikazu Ugawa; Sadatoshi Tsuji


Publisher
John Wiley and Sons
Year
2008
Tongue
English
Weight
220 KB
Volume
23
Category
Article
ISSN
0885-3185

No coin nor oath required. For personal study only.

✦ Synopsis


Abstract

Dysfunction of the basal ganglia‐thalamocortical motor circuit is a fundamental model to account for motor symptoms in Parkinson's disease (PD). Using high‐frequency repetitive transcranial magnetic stimulation (rTMS) over the supplementary motor area (SMA), we investigated whether modulation of SMA excitability engenders therapeutic effects on motor symptoms in PD. In this double‐blind placebo‐controlled study, 99 patients were enrolled and assigned randomly to SMA‐stimulation and sham‐stimulation groups. For SMA stimulation, 20 trains of 50 transcranial magnetic stimuli at 5 Hz were delivered at an intensity of 110% active motor threshold for leg muscles in one session. The sham stimulation was 20 trains of electric stimuli given through electrodes fixed on the head to mimic the cutaneous sensation during rTMS. Each session of intervention was carried out once a week for the first 8 weeks. The SMA stimulation, in contrast to the sham stimulation, engendered significant improvements in total scores and motor scores of the Unified Parkinson's Disease Rating Scale. Mean improvements in motor scores were 4.5 points in the SMA‐stimulation group and −0.1 points in the sham‐stimulation group. Results indicate that 5 Hz rTMS over SMA modestly improves motor symptoms in PD patients; SMA is a potential stimulation site for PD treatment. © 2008 Movement Disorder Society


📜 SIMILAR VOLUMES


Placebo-controlled study of rTMS for the
✍ Mikhail P. Lomarev; Sulada Kanchana; William Bara-Jimenez; Meena Iyer; Eric M. W 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 125 KB 👁 2 views

## Abstract The objective of this study is to assess the safety and efficacy of repetitive transcranial magnetic stimulation (rTMS) for gait and bradykinesia in patients with Parkinson's disease (PD). In a double‐blind placebo‐controlled study, we evaluated the effects of 25 Hz rTMS in 18 PD patien

Controlled trial on the effect of 10 day
✍ Pablo Arias; Jamile Vivas; Kenneth L. Grieve; Javier Cudeiro 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 183 KB 👁 1 views

## Abstract We evaluated the effect of low‐frequency rTMS on motor signs in Parkinson's disease (PD), under a double‐blind placebo‐controlled trial design. PD patients were randomly assigned to received either real (n = 9) or sham (n = 9) rTMS for 10 days. Each session comprises two trains of 50 st

Repetitive magnetic stimulation of corti
✍ F. Gilio; A. Currà; M. Inghilleri; C. Lorenzano; M. Manfredi; Alfredo Berardelli 📂 Article 📅 2001 🏛 John Wiley and Sons 🌐 English ⚖ 82 KB 👁 1 views

We investigated the neurophysiological and clinical effects of repetitive magnetic stimulation (rTMS) delivered to the cortical motor areas in healthy subjects and patients with Parkinson's disease. rTMS was delivered with a high speed magnetic stimulator (Cadwell, Kennewick, WA) through a figure-ei

The Movement Disorder Society Evidence-B
✍ Susan H. Fox; Regina Katzenschlager; Shen-Yang Lim; Bernard Ravina; Klaus Seppi; 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 410 KB 👁 1 views

## Abstract The objective was to update previous evidence‐based medicine reviews of treatments for motor symptoms of Parkinson's disease published between 2002 and 2005. Level I (randomized, controlled trial) reports of pharmacological, surgical, and nonpharmacological interventions for the motor s

The Movement Disorder Society Evidence-B
✍ Klaus Seppi; Daniel Weintraub; Miguel Coelho; Santiago Perez-Lloret; Susan H. Fo 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 420 KB 👁 1 views

## Abstract The __Movement__ Disorder Society (MDS) Task Force on Evidence‐Based Medicine (EBM) Review of Treatments for Parkinson's Disease (PD) was first published in 2002 and was updated in 2005 to cover clinical trial data up to January 2004 with the focus on motor symptoms of PD. In this revis